Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Doctors Urge Caution In Interpreting FDA’s SGLT2 Warning

Executive Summary

Endocrinologists raise concerns over FDA case reports because diabetic ketoacidosis may be a risk for type 1 diabetes patients taking SGLT2 inhibitors, but it is very rare in type 2 diabetes.

You may also be interested in...



FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change

FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.

FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire

The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.

FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet

Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel